Jobs
-
According to an article published March 15, 2018 in the Journal of Psychopharmacology, a pilot trial of intranasal ketamine for the treatment of severe depression conducted by researchers from the University of New South Wales… Read more . . .
-
Savara, which just announced the discontinuation of its Aironite development program after the failure of a Phase 2 trial to meet its endpoint, says that it has initiated a Phase 2a clinical study of Molgradex… Read more . . .
-
Windtree Therapeutics and Eleison Pharmaceuticals will jointly evaluate the feasibility of delivering Eleison’s inhaled lipid cisplatin (ILC) for the treatment of lung cancer via Windtree’s proprietary pulmonary aerosol delivery system (ADS), the companies said. A… Read more . . .
-
Copley Scientific has announced the appointment of an experienced lean manufacturing consultant, Richard Postlethwaite, as Chief Operating Officer. Postlethwaite was most recently Senior Operations Manager of Walgreens Boots Alliance and previously held a number of… Read more . . .
-
UK-based Avillion announced that it has signed a deal with AstraZeneca subsidiary Pearl Therapeutics for development of Pearl’s PT027 budesonide/albuterol MDI for the treatment of asthma. Avillion will finance clinical development and the regulatory submission.… Read more . . .
-
Savara has announced that the Phase 2 INDIE study of Aironite sodium nitrite inhalation solution for the treatment of heart failure with preserved ejection fraction (HFpEF) failed meet its primary endpoint and, as a result,… Read more . . .
-
Inhaled insulin developer Dance Biopharm has announced that Diplomat Specialty Pharmacy Chairman Benjamin Wolin has joined its board of directors. In 2002, Wolin co-founded digital marketing company Everyday Health and led the company until its… Read more . . .
-
According to Hikma Pharmaceuticals, the FDA has concluded the dispute resolution process regarding HIkma’s ANDA for its generic version of the Advair fluticasone propionate/salmeterol DPI and has requested a new clinical study. The FDA issued… Read more . . .
-
Aradigm has submitted a marketing authorization application to the EMA for Linhaliq dual release inhaled ciprofloxacin for the treatment of chronic P. aeruginosa lung infections in non-cystic fibrosis bronchiectasis (NCFBE) patients, the company said. In… Read more . . .
-
A Type II variation application for the use of the Relvar Ellipta fluticasone furoate/vilanterol DPI in patients whose asthma is adequately controlled by an ICS/LABA combination has been approved by the EC, according to GSK… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA